SLK inhibitors belong to a class of chemical compounds designed to target and modulate the activity of the SLK protein, which stands for Ste20-like kinase. SLK is a member of the serine/threonine kinase family, specifically the STE20 kinase subgroup, and is involved in the regulation of various cellular processes, including cell cycle progression, cytoskeletal dynamics, and cell adhesion. SLK is primarily localized in the cytoplasm and plays a crucial role in signal transduction pathways that govern cell growth, migration, and response to environmental cues. Inhibitors of SLK are developed to interfere with its kinase activity or other functions, which can potentially impact the cellular processes and signaling pathways regulated by SLK.
The mechanisms by which SLK inhibitors function can vary based on their chemical structures and binding properties. Some inhibitors may interact directly with SLK, disrupting its kinase activity or its interactions with specific substrates or regulatory proteins. Others may modulate the subcellular localization or stability of SLK, affecting its participation in signaling cascades. By inhibiting SLK, these compounds have the potential to influence cell behaviors such as proliferation, migration, and cytoskeletal rearrangements, which are crucial for normal cellular functions and responses to extracellular signals. Ongoing research in this field aims to elucidate the precise mechanisms and downstream effects of SLK inhibition, furthering our understanding of its role in cellular biology and signaling pathways.
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine, a potent kinase inhibitor, may influence SLK expression indirectly through its broad effects on cellular signaling pathways. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I, a PKC inhibitor, could potentially affect SLK expression by altering protein kinase C (PKC) mediated signaling pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, a p38 MAPK inhibitor, may modulate SLK expression by affecting the p38 MAPK pathway, which is linked to cellular stress responses. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, could influence SLK expression through its impact on the JNK signaling pathway, involved in apoptosis and cell survival. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632, a ROCK inhibitor, might alter SLK expression as part of its action on Rho-associated kinases, which are involved in cytoskeletal dynamics. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, could potentially affect SLK expression by modulating PI3K/Akt signaling pathways involved in cell survival and migration. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, may influence SLK expression as part of its broad effects on cell growth and autophagy. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib, an EGFR inhibitor, might impact SLK expression through its effects on EGFR signaling, which is linked to cell migration and proliferation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib, a Src family kinase inhibitor, could modulate SLK expression by regulating signaling pathways associated with cell migration and survival. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib, a tyrosine kinase inhibitor, may affect SLK expression through its broad impact on cellular signaling and proliferation. |